《大行》建銀國際升小米(01810.HK)目標價至67元 受惠內地消費補貼
建銀國際研究報告指,小米(01810.HK)首季業績一如預期中強勁,收入按年升47%,由各業務、尤其是物聯網的增長帶動。展望未來表現,該行料2025及22026年智能手機出貨量將分別升5%及8%,物聯網業務增長分別為30%及20%,而互聯網服務則分別增長7%及6%。電動車方面,該行預期2025及26年出貨量為35萬輛及44萬輛。
報告指,預料小米會是政府對智能手機和電子產品補貼的主要受益者,料毛利率將保持強勁,因高端產品的滲透率提高;將2025、2026及2027年的盈利預測分別上調8%、5%和9%,目標價由65元升至67元,維持「跑贏大市」評級,並籲留意新車型YU7推出。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.